Darius Kharabi Sells 2,021 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) insider Darius Kharabi sold 2,021 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $15,420.23. Following the sale, the insider now owns 67,807 shares of the company’s stock, valued at $517,367.41. This represents a 2.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

KALA BIO Stock Up 2.1 %

KALA stock traded up $0.16 during trading on Tuesday, reaching $7.69. The stock had a trading volume of 45,377 shares, compared to its average volume of 105,019. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. The firm has a fifty day moving average price of $6.71 and a 200 day moving average price of $6.32. The company has a market capitalization of $35.45 million, a P/E ratio of -0.62 and a beta of -2.11. KALA BIO, Inc. has a 1-year low of $4.21 and a 1-year high of $9.25.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50. On average, equities analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research note on Friday, November 15th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for approximately 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is owned by institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.